# CarboCode S.A

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/carbocode-s-a

- Industry: Biotechnology
- Headquarters: Cantanhede, Portugal
- Website: www.carbocode.com
- Total disclosed funding: $16M
- Latest round: Series C (Dec 4, 2024)
- Investors on record: 1

## About

Established in 2017 and based in Portugal, CarboCode Germany GmbH operates as a biotechnology company that researches, develops, and manufactures clinical evidence and enzyme technology for human sphingolipid production. In December 2024, CarboCode Germany GmbH raised EUR 15 million in Series C funding led by Iberis Capital.

The company's primary offerings include a range of ceramides aimed at improving skin health and addressing major skin disorders, human milk gangliosides for infant nutrition, and human brain gangliosides that support cognitive functions and neuronal plasticity. These products are formulated using innovative biotechnology and chemistry, allowing for scalable production while ensuring they meet the physiological needs of the human body. CarboCode's client base includes manufacturers of skin care products and infant formula, as well as pharmaceutical companies, primarily targeting markets in Europe, North America, and Asia, where the demand for biologically relevant ingredients in health products is rapidly growing.

CarboCode generates revenue through partnerships with companies in the skin care, infant nutrition, and cognitive health sectors, facilitating a business model centered around B2B transactions. The company engages in direct sales and distribution agreements with manufacturers and formulators who incorporate its sphingolipid products into their offerings.

In December 2024, CarboCode Germany GmbH raised EUR 15.00 mn in Series C funding to secure regulatory approvals, expand its research and development team, and support the launch of its first-generation products. The company is strategically planning to introduce new products to enhance its portfolio and expand into markets in North America and Asia by the end of 2025.

## Funding rounds

- Series C, Dec 4, 2024, $16M — Iberis Capital

## Investors

- Iberis Capital (https://capitalatlas.ai/funds/iberis-capital) — Series C